Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $63.84 million. The enterprise value is $22.04 million.
Important Dates
The next estimated earnings date is Tuesday, August 19, 2025, before market open.
| Earnings Date | Aug 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 59.66 million shares outstanding. The number of shares has increased by 29.23% in one year.
| Current Share Class | 59.66M |
| Shares Outstanding | 59.66M |
| Shares Change (YoY) | +29.23% |
| Shares Change (QoQ) | +11.61% |
| Owned by Insiders (%) | 4.09% |
| Owned by Institutions (%) | 27.69% |
| Float | 49.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.28 |
| Forward PS | 4.25 |
| PB Ratio | 9.59 |
| P/TBV Ratio | 12.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.98
| Current Ratio | 1.98 |
| Quick Ratio | 1.92 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.45 |
Financial Efficiency
Return on equity (ROE) is -167.55% and return on invested capital (ROIC) is -64.84%.
| Return on Equity (ROE) | -167.55% |
| Return on Assets (ROA) | -45.36% |
| Return on Invested Capital (ROIC) | -64.84% |
| Return on Capital Employed (ROCE) | -151.76% |
| Revenue Per Employee | $758,389 |
| Profits Per Employee | -$3.26M |
| Employee Count | 18 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.76% in the last 52 weeks. The beta is 0.29, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -34.76% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 46.10 |
| Average Volume (20 Days) | 168,472 |
Short Selling Information
The latest short interest is 495,953, so 0.83% of the outstanding shares have been sold short.
| Short Interest | 495,953 |
| Short Previous Month | 1.04M |
| Short % of Shares Out | 0.83% |
| Short % of Float | 1.00% |
| Short Ratio (days to cover) | 3.44 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $13.65 million and -$58.62 million in losses. Loss per share was -$2.02.
| Revenue | 13.65M |
| Gross Profit | -16.35M |
| Operating Income | -36.30M |
| Pretax Income | n/a |
| Net Income | -58.62M |
| EBITDA | -36.27M |
| EBIT | -36.30M |
| Loss Per Share | -$2.02 |
Full Income StatementBalance Sheet
The company has $41.79 million in cash and n/a in debt, giving a net cash position of $41.79 million or $0.70 per share.
| Cash & Cash Equivalents | 41.79M |
| Total Debt | n/a |
| Net Cash | 41.79M |
| Net Cash Per Share | $0.70 |
| Equity (Book Value) | 23.92M |
| Book Value Per Share | 0.11 |
| Working Capital | 23.68M |
Full Balance SheetCash Flow
| Operating Cash Flow | -28.85M |
| Capital Expenditures | n/a |
| Free Cash Flow | -28.85M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
| Gross Margin | -119.74% |
| Operating Margin | -265.88% |
| Pretax Margin | -429.42% |
| Profit Margin | n/a |
| EBITDA Margin | -265.72% |
| EBIT Margin | -265.88% |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.23% |
| Shareholder Yield | -29.23% |
| Earnings Yield | -91.83% |
| FCF Yield | -45.20% |
Analyst Forecast
The average price target for Opus Genetics is $6.33, which is 491.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.33 |
| Price Target Difference | 491.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 28.37% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -4.93 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.93 |
| Piotroski F-Score | 1 |
